IL-12 Influence mTOR to Modulate CD8+ T Cells Differentiation through T-bet and Eomesodermin in Response to Invasive Pulmonary Aspergillosis

Int J Med Sci. 2017 Aug 18;14(10):977-983. doi: 10.7150/ijms.20212. eCollection 2017.

Abstract

Objective: To investigate whether mTOR signaling pathway regulate the proliferation and differentiation of CD8+ T cells by transcription factors T-bet and Eomes, and explore the role of IL-12 in this biological procedure. Methods: Aspergillus fumigatus spore suspension nasal inhalation was used to establish the invasive pulmonary aspergillosis (IPA) mouse model. After inoculation, rapamycin (2mg/kg) each day or IL-12 (5ug/kg) every other day was given for 7 days. The blood samples were obtained before the mice sacrificed and lung specimens were taken. Pathological sections were stained with hematoxylin and eosin (HE). The number of CD8+effective memory T cells (Tem) and the expression of IFN-γ, mTOR, ribosomal protein S6 kinase (S6K), T-bet and EOMES were measured by flow cytometry. The levels of IL-6, IL-10 and Galactomannan (GM) were determined by ELISA. Results: After IL-12 treatment, the number of CD8+ Tem and the expression of IFN-γ increased significantly; while quite the opposite results were observed when the mTOR pathway was blocked by rapamycin. The expression of mTOR and S6K as well as the level of IFN-γ of the IL-12 treatment group were significantly higher than those in IPA and IPA + rapamycin groups. In addition, IL-12 promoted increasing T-bet and down regulating Eomes to make the Tem transformation. The final immune effector was high level of inflammatory cytokines (IL-6) and low level of anti-inflammatory factors (IL-10) and this strengthened immune response to the Aspergillus infection. Conclusions: The biological effects of Tem could significantly affect IPA infection host immune regulation, which depended on the activation of mTOR signaling pathway by IL-12.

Keywords: CD8+effect memory T cells (Tem); IL-12; Invasive Pulmonary Aspergillosis (IPA).; Mammalian target of rapamycin (mTOR).

MeSH terms

  • Animals
  • Antifungal Agents / therapeutic use
  • Aspergillus fumigatus / pathogenicity
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / metabolism*
  • Cell Differentiation / immunology
  • Disease Models, Animal
  • Down-Regulation
  • Female
  • Humans
  • Interferon-gamma / blood
  • Interferon-gamma / immunology
  • Interferon-gamma / metabolism
  • Interleukin-10 / blood
  • Interleukin-10 / immunology
  • Interleukin-12 / immunology
  • Interleukin-12 / metabolism*
  • Interleukin-6 / blood
  • Interleukin-6 / immunology
  • Invasive Pulmonary Aspergillosis / blood
  • Invasive Pulmonary Aspergillosis / drug therapy
  • Invasive Pulmonary Aspergillosis / immunology*
  • Invasive Pulmonary Aspergillosis / microbiology
  • Lung / microbiology
  • Lung / pathology
  • Mice
  • Mice, Inbred BALB C
  • Ribosomal Protein S6 Kinases / immunology
  • Ribosomal Protein S6 Kinases / metabolism
  • Signal Transduction / immunology
  • Sirolimus / therapeutic use
  • T-Box Domain Proteins / immunology
  • T-Box Domain Proteins / metabolism*
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism*
  • TOR Serine-Threonine Kinases / immunology
  • TOR Serine-Threonine Kinases / metabolism*

Substances

  • Antifungal Agents
  • Eomes protein, mouse
  • IFNG protein, mouse
  • IL10 protein, mouse
  • Interleukin-6
  • T-Box Domain Proteins
  • T-box transcription factor TBX21
  • interleukin-6, mouse
  • Interleukin-10
  • Interleukin-12
  • Interferon-gamma
  • mTOR protein, mouse
  • Ribosomal Protein S6 Kinases
  • TOR Serine-Threonine Kinases
  • Sirolimus